* A study in Greece involved 184 adults, revealing that many suffer from additional issues like obesity and allergic comorbidities, with the majority receiving specific treatment for their condition.
* Key findings included high rates of pain, severe itching, and sleep disturbances, with patients reporting substantial reductions in work productivity and overall well-being.
* A thorough literature review identified 12 studies (10 on dupilumab, 2 on JAK inhibitors) and evaluated their effects on skin barrier metrics like transepidermal water loss and hydration, with a total of 416 participants across various study designs.
* Results showed that dupilumab significantly reduced transepidermal water loss and improved skin hydration, highlighting the effectiveness of IL-4/IL-13 inhibitors, while the data on JAK inhibitors is limited, suggesting further research is needed